AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
Portfolio Pulse from Vandana Singh
The FDA has approved AstraZeneca and Sanofi's Beyfortus for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The approval covers children up to 24 months of age. Beyfortus was approved in the EU in November 2022 and applications are under review in China, Japan, and other countries. The drug will be available in the US before the 2023-2024 RSV season.
July 18, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Beyfortus has received FDA approval, potentially boosting the company's revenues.
The FDA approval of Beyfortus is a significant milestone for AstraZeneca. This could lead to increased sales and revenues for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Sanofi's Beyfortus has received FDA approval, potentially boosting the company's revenues.
The FDA approval of Beyfortus is a significant milestone for Sanofi. This could lead to increased sales and revenues for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100